BridgeBio Pharma’s (BBIO) “Overweight” Rating Reiterated at Cantor Fitzgerald
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. They currently have a $95.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 157.80% from the stock’s current price. Other research analysts also recently […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. They currently have a $95.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 157.80% from the stock’s current price. Other research analysts also recently […]
